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Abstract
Background: cAMP-dependent protein kinase (PKA) has been implicated in the asexual stage of the Toxoplasma gondii life
cycle through assaying the effect of a PKA-specific inhibitor on its growth rate. Since inhibition of the host cell PKA cannot
be ruled out, a more precise evaluation of the role of PKA, as well as characterization of the kinase itself, is necessary.
Methodology/Principal Finding: The inhibitory effects of two PKA inhibitors, H89, an ATP-competitive chemical inhibitor,
and PKI, a substrate-competitive mammalian natural peptide inhibitor, were estimated. In the in vitro kinase assay, the
inhibitory effect of PKI on a recombinant T. gondii PKA catalytic subunit (TgPKA-C) was weaker compared to that on
mammalian PKA-C. In a tachyzoite growth assay, PKI had little effect on the growth of tachyzoites, whereas H89 strongly
inhibited it. Moreover, T. gondii PKA regulatory subunit (TgPKA-R)-overexpressing tachyzoites showed a significant growth
defect.
Conclusions/Significance: Our data suggest that PKA plays an important role in the growth of tachyzoites, and the
inhibitory effect of substrate-competitive inhibitor PKI on T. gondii PKA was low compared to that of the ATP competitive
inhibitor H89.
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Introduction
Toxoplasma gondii is an obligate intracellular apicomplexan
parasite that is an important pathogen of humans and animals.
T. gondii causes encephalitis in immunocompromised patients, and
progressive encephalitis in children infected in utero [1,2]. The life
cycle of T. gondii consists of two phases: the sexual, which takes
place only in felines, and the asexual, which takes place in all
mammalian and avian hosts [3]. In the asexual phase, the parasite
switches between two different developmental forms. The
tachyzoite is the rapidly growing form of the parasite and is
responsible for the infection and toxoplasmosis. Tachyzoites
multiply asexually, invade host cells, and are distributed via the
blood stream and lymphatic system throughout the body. In
healthy animals, the infection is normally controlled by the
immune system. After being triggered by the immune system,
tachyzoites differentiate into slow-growing, encysted bradyzoites,
which reside in the central nervous system and muscle tissue for
the life of the host, hidden from the immune system [4]. In
immunocompromised patients, such as those with human
immunodeficiency virus (HIV) infection, bradyzoites can reacti-
vate and differentiate into tachyzoites, leading to a severe
toxoplasmosis [5]. Although drugs for treatment of toxoplasmosis
are available, they are poorly tolerated, have severe side effects,
and cannot act against chronic Toxoplasma infections [6,7].
Therefore, new anti-T. gondii drugs are urgently needed. Studies
on the basic biology of this organism are thus necessary for
discovery of novel targets, and may also serve as a model system
for the study of other apicomplexan parasites.
Eukaryotic signaling pathways regulate a spectrum of intracel-
lular activities; for example, the cAMP-dependent pathway is
known to influence gene expression, apoptosis, tissue differentia-
tion, and cellular proliferation [8]. The main enzymatic
component of this signaling pathway is cAMP-dependent protein
kinase (PKA). In its non-active form, PKA is a tetramer composed
of two catalytic subunits (PKA-C) and two regulatory subunits
(PKA-R). Binding of cAMP to PKA-R, each subunit of which
contains two cAMP-binding sites, releases the PKA-C subunits,
resulting in their activation [9]. In addition to the PKA-R
subunits, PKA-C activity is regulated through the binding of its
natural peptide inhibitor, protein kinase A inhibitor (PKI). PKI
contains pseudosubstrate sites, which allows it to bind to PKA-C
with high affinity and inhibit PKA-C activity by competing with its
substrate [10].
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components in the life cycles of many eukaryotic pathogens. In
Plasmodium falciparum, cAMP has been implicated in the differen-
tiation of gametocytes [11], and PKA activity might be necessary
for completion of the asexual cycle or reinvasion of erythrocytes
[12]. A key role for PKA in regulating parasite differentiation and
gene expression has also been indicated in Leishmania major [13,14],
Giardia lamblia [15], and Schistosoma mansoni [16,17]. In T. gondii,
studies using cAMP analogs and cyclic nucleotide phosphodies-
terase (PDE) inhibitors, which inhibit inactivation of cAMPs,
implicated cAMP signaling in the asexual stage of the parasite
[18]. Recently, H89, a specific inhibitor of PKA, was reported to
cause decreased bradyzoite differentiation and replication of
tachyzoites [19]. Although these data indicate a possible role of
cAMP and PKA in the asexual cycle of T. gondii, whether these
effects are extracellular (i.e., host-mediated), intracellular (i.e.,
within the parasite), or due to stimulation of both host and parasite
signaling pathways remains to be determined. Moreover, although
H89 is considered to be a specific inhibitor of PKA, several recent
reports have suggested that H89 inhibits other kinases such as
mitogen- and stress-activated protein kinase 1, p70 ribosomal
protein S6 kinase or Rho-dependent protein kinase II [20,21,22].
Therefore, H89 should not be the single source of evidence for
PKA involvement.
In this study, we compared the inhibitory effects of ATP
competitive chemical inhibitor H89 and mammalian natural
peptide inhibitor PKI in an in vitro kinase assay using recombinant
T. gondii PKA catalytic subunit (TgPKA-C), as well as tachyzoite
growth assay. The effect of PKI was weaker in TgPKA-C
compared to mammalian PKA-C in the in vitro kinase assay, and
PKI did not inhibit tachyzoite growth. These data support the
hypothesis that the inhibitory effect of H89 on tachyzoite growth is
due to TgPKA-C inhibition, since the possible inhibition of host
cell PKA-C activity by PKI did not result in the inhibition of
tachyzoite growth. Moreover, we generated a parasite line that
expressed TgPKA-R stably, in which inhibiting the activity of
parasite PKA without any effect on host cell PKA might be
possible. These parasites also showed decreased growth. According
to these data, TgPKA-C does indeed play an important role in the
asexual stage of the T. gondii life cycle.
Results
Identification of TgPKA-C
The amino acid sequence alignment of the putative TgPKA-C
(ToxoDB identifier; TGGT1_081170), which we identified for the
first time, is shown in Figure 1 together with those of P. falciparum
and Homo sapiens. The putative TgPKA-C (343 amino acid
residues) showed 54% identity with H. sapiens PKA-Ca (HsPKA-
Ca, GenBank Accession Number: NP_002721) and 57% identity
with P. falciparum PKA-C (PfPKA-C, GenBank Accession Number:
AAB70118). A multiple alignment using the ClustalW program
showed that the 11 major subdomains of protein kinases (I–XI)
[23] are conserved in the amino acid sequence of TgPKA-C.
Moreover, highly conserved individual amino acids that are
involved in ATP binding, peptide binding, stabilizing, or
autophosphorylation were also seen in TgPKA-C amino acid
sequences [24,25].
Identification of TgPKA-R
Figure 2A shows the general domain structure of a mammalian
PKA-R. PKA-R is an multi-domain protein composed of a
dimerization/docking (D/D) domain at the N terminus [the
docking site for A-kinase anchor proteins (AKAPs)], followed by
an inhibitory site (for binding PKA-C) and two cAMP-binding
domains, A and B [26]. An amino acid sequence alignment of the
predicted TgPKA-R with those of P. falciparum and H. sapiens,i s
shown in Figure 2B. The predicted TgPKA-R (ToxoDB identifier:
TGGT1_048350) (386 amino acid residues) showed 37% identity
with H. sapiens PKA regulatory subunit Ia (HsPKA-RIa, GenBank
Accession Number: NP_002725), 35% identity with HsPKA-RIIa
(GenBank Accession Number: NP_004148), 36% identity with
HsPKA-RIb (GenBank Accession Number: NP_001158230), and
32% identity with HsPKA-RIIb (GenBank Accession Number:
NP_002727), as well as 52% identity with P. falciparum PKA-R
(PfPKA-R, GenBank Accession Number: AJ441326). TgPKA-R
possessed the two most conserved regions of PKA-R: the
phosphate-binding cassettes (PBCs) of cAMP-binding domains A
and B, specific to proteins of the PKA-R family [27]. The TgPKA-
R amino acid sequence also harbored a site of inhibition, which
contained a phosphorylatable serine, a feature characteristic of the
RII subunit of mammalian PKA. In contrast, a D/D domain was
not detected in TgPKA-R.
Expression and purification of TgPKA-C in the wheat
germ cell-free protein synthesis system
To characterize the function of the protein, we expressed and
purified TgPKA-C as a GST fusion protein using a wheat germ
cell-free protein synthesis system. Purified protein was then
electrophoretically separated in a denaturing gel and either
silver-stained or immunoblotted with rabbit antiserum containing
a-GST antibody (Figure 3A). The purified proteins from the wheat
germ extracts after cell-free protein synthesis with either pEU-
GST-GFP [for the expression of GST and green fluorescence
protein (GFP) fusion protein] or pEU-GST-TgPKA-C contained
one major purified protein with an Mr of 53,000 or 69,000,
respectively, as detected by silver staining. These proteins reacted
with antiserum containing a-GST antibody. These data indicate
that we successfully purified the desired GST fusion proteins.
Protein kinase activity of purified TgPKA-C
Many protein kinases possess autophosphorylating activity [28].
Autophosphorylation of PKA-C is necessary for its enzymatic
activation [29] and interaction with PKA-R [30]. We thus used a
kinase assay to determine whether purified TgPKA-C did in fact
possess such activity. Purified GST–GFP fusion protein, which was
incubated in kinase buffer and electrophoretically separated, did
not contain any labeled bands (Figure 3B, lane 1). However, in the
autoradiographic image of purified TgPKA-C, a protein band
with an apparent Mr of 69 000 was labeled (Figure 3B, lane 2).
The electrophoretic mobility of labeled TgPKA-C was the same as
that of purified TgPKA-C stained with Coomassie brilliant blue
(CBB; Figure 3B). To determine if the labeling of TgPKA-C with
[c-
32P]ATP was due to phosphorylation, labeled TgPKA-C was
boiled to inactivate kinases and incubated with l-protein
phosphatase (New England Biolabs, Ipswich, MA) in accordance
with the manufacturer’s instructions. The labeled TgPKA-C band
was eliminated by phosphatase treatment, indicating that TgPKA-
C was labeled with [c-
32P]ATP via phosphorylation (Figure 3C).
These data suggested that TgPKA-C levels remained relatively
unchanged after boiling, and so boiling did not result in loss of
TgPKA-C. Thus, TgPKA-C phosphorylates itself and indeed
possesses protein kinase activity. Next, we investigated whether
TgPKA-C has the ability to phosphorylate other substrate(s).
When histone IIAS was used as a representative substrate for
protein kinase, it was labeled by TgPKA-C (Figure 3D, lane 2), but
not by GFP (Figure 3D, lane 1). The expression of each GST
fusion protein and histone IIAS and the identity of the radiolabeled
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reaction was seen only in the case of histone IIAS phosphorylated
by TgPKA-C (Figure 3D, lane 2) as no protein contamination was
detected in the migration range of histone IIAS in the lane of
purified GFP (Figure 3D, lane 1). These results indicate that
TgPKA-C possesses the ability to phosphorylate both itself and
other substrate(s).
Susceptibility of recombinant TgPKA-C to PKA-specific
inhibitors
An inhibition assay was used to estimate the effect of PKA
specific inhibitors on TgPKA-C. As shown in Figure 4A, inhibition
assays of TgPKA-C by H89 was performed on the concentrations
of 400, 200, 100, 50 and 25 mM. The estimated IC50 was 175 mM,
which might be much higher than that of mammal PKA [31].
Inhibitory assay of PKI was performed in the presence or absence
of 100 mM PKI5-24. In addition to TgPKA-C, Bos taurus PKA-C
(BtPKA-C; Promega, Madison, WI) was included as a positive
control. Compared to BtPKA-C, inhibition by PKI was much
weaker in TgPKA-C (Figure 4B). These data indicate that
susceptibility of TgPKA-C on both inhibitors differs from that of
mammalian PKA-C.
Effect of PKA-C inhibitors on the growth of parasites
To investigate the role of TgPKA in the asexual stage, we
performed a tachyzoite growth assay in the presence of H89 and
PKI. Tachyzoites treated with H89 have been reported to show an
increased doubling time [19], indicating a potential role of TgPKA
in replication. However, an effect of H89 on host cell PKA still
cannot be ruled out, since mammalian PKA showed high
susceptibility to H89 in the in vitro kinase assay (Figure 4B). To
clarify whether the growth defect was due to inhibition of T. gondii
Figure 1. Identification of TgPKA-C. Comparison of predicted TgPKA-C amino acid sequences (ToxoDB identifier; TGGT1_081170) with those of P.
falciparum PKA-C (PfPKA-C, GenBank Accession Number: AAB70118) and H. sapiens PKA-Ca (HsPKA-Ca, GenBank Accession Number: NP_002721).
Amino acid identity (black boxes) and similarity (gray boxes) are shown within the protein kinase domain. Gaps introduced to optimize alignments
are marked by dashes. Roman numerals indicate the 11 conserved protein kinase subdomains [23]. The 12 most highly conserved residues are
highlighted with filled triangles. The sequence thought to be necessary for binding to mammalian PKI is shown with a dotted line.
doi:10.1371/journal.pone.0022492.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22492Figure 2. Identification of TgPKA-R. A, Schematic linear domain structure of a mammalian PKA-R. The N-terminal dimerization domain, inhibitory
site, cAMP-binding domain A, and cAMP-binding domain B are shown. B, Comparison of predicted TgPKA-R amino acid sequences (ToxoDB identifier:
TGGT1_048350) with those of P. falciparum PKA-R (PfPKA-R, GenBank Accession Number: AJ441326) and H. sapiens PKA-R isoforms Ia (HsPKA-RIa,
GenBank Accession Number: NP_002725), Ib (GenBank Accession Number: NP_001158230), IIa (GenBank Accession Number: NP_004148), and IIb
(GenBank Accession Number: NP_002727). Amino acid identity (black boxes) and similarity (gray boxes) are shown within the protein kinase domain.
Gaps introduced to optimize alignments are marked by dashes. The conserved phosphate-binding cassettes of cAMP-binding domains A (PBC-A) and B
(PBC-B) are shown with a solid line, and the inhibitory sequence is indicated by a dotted line. The phosphorylable serine is indicated by a black arrow.
doi:10.1371/journal.pone.0022492.g002
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22492Figure 3. Expression, purification and kinase activity of TgPKA-C. A, A silver-stained ge and an immunoblot of purified GST-GFP or GST-
TgPKA-C generated in the wheat germ cell-free protein synthesis system using pEU-GST-GFP (lanes 1 and 2) or pEU-GST-TgPKA-C (lanes 3 and 4).
Total wheat germ extracts (lanes 1 and 3) were subjected to affinity chromatography on glutathione-Sepharose beads (lanes 2 and 4). The proteins
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in a tachyzoite growth assay. Since PKI5–24, which we used in the
in vitro kinase assay, is not cell-permeable, we used the cell-
permeable, myristolated PKI14–22. The final concentration of both
H89 [19] and PKI was 2 mM. Figure 5 shows the average parasite
number per parasitophorous vacuole (P/V) at 12, 24, and 36 h
post-invasion. Vacuoles containing more than 32 parasites were
calculated as 32 P/V, since above this value discriminating
individual parasites became problematic. The average P/V in
controls was 1.71, 6.22, and 28.3 at each time point. In dimethyl
sulfoxide (DMSO)-treated parasites (a vehicle of H89), the average
P/V was 1.64, 6.90, and 27.7 at each time point, similar to those
of the control parasites. The average P/V of H89-treated parasites
was markedly lower (1.63, 4.61, and 10.7). The growth rate of
were separated on denaturing gels and subjected to silver staining or transferred onto a nitrocellulose sheet and reacted with the anti-GST antibody.
Molecular masses (kDa) are shown on the left. B, Purified GST-GFP (lane 1) or GST-TgPKA-C (lane 2) was incubated in kinase buffer containing
[c-
32P]ATP, separated on a denaturing gel, and Coomassie stained (left panel). Autoradiograph of the gel (right panel). Arrows indicate the migration
of GST-TgPKA-C and GST-GFP. C, Purified GST-TgPKA-C was incubated in kinase buffer (lane 1). The labeled protein was treated with l-protein
phosphatase (lane 2). Reaction mixtures were then subjected to resolution on an 8% SDS-PAGE gel, followed by Coomassie staining (left panel).
Autoradiograph of the gel (C). D, Purified GST-GFP (lane 1) or GST-TgPKA-C (lane 2) was incubated in kinase buffer with Histone IIAS and separated on
a 15% denaturing gel followed by Coomassie staining (left panel). Autoradiograph of the gel (right panel). Molecular masses (kDa) are shown on the
left.
doi:10.1371/journal.pone.0022492.g003
Figure 4. Effects of mammalian PKA inhibitors on the kinase activity of TgPKA-C in vitro. A and B, Kinase activities of TgPKA-C and BtPKA-
C were calculated in the presence of 400, 200, 100, 50 and 25 mM of H89 (A) or 100 mM of bovine PKI (B). Reactions were carried out at 30uC for
30 min and terminated by boiling in SDS-PAGE sample buffer. Reaction mixtures were then subjected to resolution by 15% SDS-PAGE followed by
Coomassie staining. Phosphate incorporation into Histone IIAS was measured by scintillation counting of excised gel fragments. Enzyme activity in the
absence of inhibitors was taken to be 100%. Representative results of three independent determinations are shown.
doi:10.1371/journal.pone.0022492.g004
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suggesting growth inhibition. This is consistent with previous
reports [19]. In contrast, in mammalian PKI-treated parasites, the
average P/V values were 1.62, 5.35, and 29.4. Since no significant
difference between the P/V of the control and PKI-treated
parasites was observed, PKI seems to have no inhibitory effect on
tachyzoite growth. This result indicates that the susceptibility of
TgPKA-C to PKI is lower than that to H89.
Interaction of recombinant TgPKA-C and TgPKA-R in vitro
To determine whether TgPKA-R interacts with TgPKA-C in
vitro, we used TgPKA-C and recombinant TgPKA-R in an in vitro
kinase assay. We first expressed TgPKA-R as an MBP fusion
protein. Next, we incubated purified MBP-TgPKA-R with GST-
TgPKA-C. MBP-b-gal-a was used as a negative control. As shown
in Figure 6A, lane 1, MBP-b-gal-a did not show evidence of a
positive reaction. However, in the autoradiographic image of
purified MBP-TgPKA-R, a protein band with an apparent Mr of
86,000 was labeled (Figure 6B, lane 2). These data demonstrate
that TgPKA-C phosphorylates TgPKA-R in vitro.
Growth assay of TgPKA-R-overexpressing parasites
To clarify the role of TgPKA in the asexual stage of the T. gondii
life cycle, inhibiting its kinase activity without affecting the host cell
is necessary. We hypothesized that an excess of PKA regulatory
subunits may inhibit the activity of catalytic subunits. Therefore,
we generated a T. gondii line that overexpresses TgPKA-R. The
derived line was designated RH/TgPKA-R. RH/TgPKA-R
expressed TgPKA-R-3xFlag mRNA. Total RNA extracted from
RH/TgPKA-R contained an mRNA of approximately 1.3 kbp
(Figure 7, lane 4), as detected by RT-PCR using the primers 59-
CGAATTCGGGTAACGTTTGTGAATGCC-39 and 59-CGC-
GTTAATTAACTACTTGTCATCGTCATCC-39, whereas no
band was detected from total RNA extracted from the parental
strain RH/ht
2 (Figure 7, lane 2). When a growth assay was
performed using this RH/TgPKA-R line, a significant defect in
Figure 5. T. gondii tachyzoite growth assay. Average parasite
number per parasitophorous vacuole at 12, 24, and 36 h postinfection.
RH/PKA-R or RH/GFP parasites were added to Vero cell monolayers at a
MOI of 1:10 and incubated for 2 h at 37uC. Extracellular parasites were
then removed by washing three times with PBS(–) and returned to
culture in complete medium with or without PKA inhibitor. The final
concentration of inhibitors H89 (Promega) and PKI14-22 (Calbiochem)
was 2 mM. P/V: parasites per vacuole. Representative results of three
independent determinations are shown.
doi:10.1371/journal.pone.0022492.g005
Figure 6. Interaction of GST-TgPKA-C and MBP-TgPKA-R. A, Purified MBP-b-gal (lane 1) or MBP-TgPKA-R (lane 2) was incubated with GST-
TgPKA-C in kinase buffer containing [c-
32P]ATP, separated on a denaturing gel, and Coomassie stained. B, Autoradiograph of the gel shown in (A).
Arrows indicate the migration of GST-TgPKA-C, MBP-b-gal, or MBP-TgPKA-R. Molecular masses (kDa) are shown on the left.
doi:10.1371/journal.pone.0022492.g006
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were 1.46, 3.60, and 8.39 at 12, 24, and 36 h post-invasion,
respectively (Figure 5). Since the host cell PKA was not inhibited,
one may reasonably assume that the decreased parasite growth
rate was a result of TgPKA-C inhibition.
Discussion
We identified T. gondii PKA-C and PKA-R, which possess the
highly conserved domains in PKA-Cs or PKA-Rs of H. sapiens and
P. falciparum. GST-TgPKA-C was successfully expressed and
purified using a wheat germ cell-free protein synthesis system.
We also demonstrated that purified TgPKA-C possesses both auto
and substrate kinase activity.
We determined the effect of two PKA specific inhibitors, H89
and PKI, on TgPKA-C activity. The IC50 of H89 on TgPKA-C
was 175 mM, while that of bovine PKA-C has been reported to be
approximately 50 nM [31]. Such a difference in the IC50s might
be due to the expression system, since TgPKA-C was expressed
using the germ cell-free protein synthesis system while BtPKA-C
we used was native. Using PKI, difference in the susceptibility
could be also observed. Our data suggested that inhibition of
TgPKA-C by PKI was weak compared to mammalian PKA-C.
This is consistent with our data from P. falciparum [32]. We also
estimated the effect of H89 and mammalian PKI on tachyzoite
growth. Whereas H89 reduced the growth of tachyzoites, as
previously reported [19], PKI at the same concentration had no,
or at high concentrations, a vastly reduced effect (data not shown).
These data, together with those of the in vitro kinase assay, show
that the susceptibility of TgPKA-C to mammalian PKI was low
compared to mammalian PKA-C. Since host PKA is likely
strongly inhibited by mammalian PKI, one may reasonably
consider that host PKA inhibition has no significant effect on T.
gondii growth, at least in vitro. Therefore, the effect of H89 on
growth appears to have been due to inhibition of T. gondii PKA-C,
suggesting an important role for PKA-C in the growth of
tachyzoites.
The low susceptibility of TgPKA-C to PKI might be due to its
lack of the PKI binding sequence ‘‘DDYEEEE,’’ which lies near
the C-terminus of PKA-C (Figure 1). Lack of such a binding
sequence occurs in other apicomplexan parasites, e.g., P. falciparum
[33], Babesia bovis, Theileria annulata, and Cryptosporidium parvum.
Natural PKI in mammalian cells regulates free PKA-C not only
through its kinase activity but also by localization, such as
exporting it from the nucleus back to the cytoplasm [10,34,35].
Therefore, the lack of the PKI-binding sequence in PKA-C
suggests the existence of a different regulatory mechanism in
apicomplexan parasites. This difference in PKA-C regulation
between the apicomplexan parasites and their hosts renders PKA-
C a potential target for novel therapeutics.
Furthermore, we succeeded in constructing TgPKA-R-overex-
pressing parasites. A significant defect in the growth of these
parasites was detected. This suggests strongly that inhibition of T.
gondii, but not host cell, PKA-C was the cause of the growth
inhibition. Thus, these data support the hypothesis that T. gondii
PKA-C plays a significant role in tachyzoite replication.
The mechanism by which TgPKA-R, overexpressed in
transgenic parasites, inhibited the activity of natural PKA-C is
unclear. Two possibilities exist: TgPKA-R may act as a
pseudosubstrate of TgPKA-C by inhibiting its binding to a
substrate, or it may act as a cAMP sink, thereby reducing available
cAMP so that PKA-C cannot be dissociated from PKA-R. When
we used GST-TgPKA-C and MBP-TgPKA-R under cAMP-free
conditions in an in vitro kinase assay, no reduction in its
phosphorylation ability was observed (data not shown). However,
in the experiment in which P. falciparum lysate containing cAMPs
was used instead of recombinant TgPKA-C, phosphorylation of
PfPKA-C markedly decreased [36]. Although other factors should
be considered, the presence of cAMP may be the reason for this
difference. Therefore, the presence of elevated TgPKA-R levels
may have inhibited the activity of TgPKA-C by reducing available
cAMP.
Further understanding of the biology of TgPKA may best be
gained by investigation of the pathways and proteins with which
TgPKA-C interacts. Since PKA is known to be involved in various
activities of mammalian cells, many types of substrate may also be
present in T. gondii. Several proteins have recently been reported to
interact with PKA-C in apicomplexan parasites. In P. falciparum,
the merozoite transmembrane protein AMA1, which is involved in
the invasion of erythrocytes, has been reported to be phosphor-
ylated by PKA [37]. Since T. gondii possesses a homolog of this
protein (TgAMA1), TgPKA may also interact with it, thereby
regulating invasion. In Trypanosoma cruzi, yeast two-hybrid
experiments revealed that several proteins with known functions
interact with PKA [38,39]. These potential substrates are
presumably important for the regulation of T. cruzi growth,
adaptation, and differentiation. Since some of these proteins, for
example, hexokinase and aquapoline, also exist in T. gondii,
investigating their interaction(s) with TgPKA-C might be inter-
esting.
Materials and Methods
Cells and parasites
Tachyzoites of T. gondii RH strain and RH/ht
2 strain (kindly
provided by Dr. X. Xuan) were used in this study. Parasites were
maintained in monolayers of Vero cells cultured in Dulbecco’s
modified Eagle’s medium (DMEM) that contained 7.5% fetal calf
serum (FCS), 2 mM L-glutamine, 20 mM HEPES (pH 7.5),
Figure 7. Expression of TgPKA-R-3xFlag mRNA in RH/PKA-R.
Confirmation of the expression of TgPKA-R-3xFlag mRNA in RHPKA-R by
RT-PCR. Total RNAs extracted from RH/ht
2 or RH/PKA-R were used as
templates. PCR samples were resolved on a 1.5% agarose gel and
stained with ethidium bromide.
doi:10.1371/journal.pone.0022492.g007
Characterization of Toxoplasma gondii PKA
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22492streptomycin, and penicillin. Host Vero cells were passaged in the
same medium.
Plasmids
T. gondii RH strain mRNA was isolated from infected Vero cells
using the TRIZOL reagent (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions. The entire TgPKA-C open
reading frame (ORF) was amplified by RT-PCR using parasite
mRNA as the template and the following primers: forward,
59-CCGGCTCGAGGATCTTTTTCGCCGTCTAAT-39 and
reverse, 59-CGGGATCCTTACCACGACGTGAAAGGGT-39.
The PCR product was digested with XhoI/BamHI and cloned
into the XhoI and BamHI sites of pEU (CellFree Sciences,
Yokohama, Japan) to express a glutathione S-transferase (GST)
fusion protein. The resultant plasmid was designated pEU-GST-
TgPKA-C. The entire TgPKA-R ORF was amplified from
parasite mRNA by RT-PCR using the primers 59-CGAATT-
CGGTAACGTTTGTGAATGCCAAAAG-39 and 59-GGGCT-
GCAGTTATTTGTCGAGGTATTTGGTGTCG-39. Amplified
fragments were digested with EcoRI/PstI and cloned into the
EcoRI and PstI sites of pMal-c (New England BioLabs, Beverly,
MA) in-frame with maltose-binding protein (MBP), to generate
pMal-TgPKA-R. For stable expression, pMFH-TgPKA-R was
generated as follows. The TgPKA-R ORF attached to the EcoRI/
EcoRV restriction site was amplified from pMal-TgPKA-R using
the primers 59-CGAATTCGGGTAACGTTTGTGAATGCC-39
and 59-GGATATCTTTGTCGAGGTATTTGGTGTCG-39.
Amplified fragments were digested with EcoRI/EcoRV and cloned
into the EcoRI and EcoRV sites of pMini.36Flag.ht [40].
Wheat germ cell-free protein synthesis system
Protein expression using the Wheat germ cell-free protein
synthesis system (CellFree Sciences) was performed as described
previously [41,42]. Briefly, at the transcription step, 2 mg of pEU-
GST-GFP or pEU-GST-TgPKA-C was mixed with 18 mL
transcription mixture (transcription buffer with 2.5 mM NTP
mix, 1 U/mL RNase inhibitor, 1 U/mL SP6 RNA polymerase;
CellFree Sciences) and incubated at 37uC for 6 h. Each mRNA
generated was then mixed with 10.8 mL WEPRO1240G (CellFree
Sciences) and 40 ng/mL creatine kinase (Roche, Mannheim,
Germany), then transferred to the bottom of the SUB-AMIX
(CellFree Sciences) to form a bilayer and incubated at 16uC for
20 h.
Purification of recombinant proteins
Wheat germ extracts were mixed with 15 mL of a 50% slurry
of glutathione sepharose beads (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) for 16 h. The beads were then washed
three times with phosphate-buffered saline (PBS)(–). Purified
protein captured on the beads was separated by 10% SDS-
PAGE after boiling and either silver-stained or immunoblotted
(Figure 3A) with a-GST antibody (Sigma-Aldrich, St. Louis,
MO). Purification of recombinant protein expressed in Esche-
richia coli DH5a transformed with plasmids harboring MBP-
TgPKA-R was performed according to the manufacturer’s
instructions. Briefly, bacterial cells cultured with 0.1 mM
isopropyl b-D-1-thiogalactopyranoside (IPTG) at 37uCf o r2h
were pelleted and solubilized in 1% Tween 20/PBS(–) using one
freeze–thaw cycle and three 10 s bursts of ultrasonication. After
centrifugation (10,500 rpm, 4uC, 10 min), the supernatant was
mixed with amylose resin beads (New England BioLabs) at 4uC
for 2 h, and the beads washed five times with 1% Tween
20/PBS(–).
In vitro kinase assay
Purified GST-GFP or GST-TgPKA-C captured on glutathione-
Sepharose beads was rinsed twice with washing buffer [50 mM
Tris–HCl (pH 9.0), 2 mM dithiothreitol (DTT)]. Reactions were
performed at 30uC for 30 min in a total volume of 50 mL kinase
buffer [50 mM Tris–HCl (pH 8.0), 200 mM NaCl, 50 mM
MgCl2, 0.1% Nonidet P-40, 1 mM DTT] containing 5 mCi
[c-
32P] ATP. Samples were then washed with TNE buffer
[20 mM Tris–HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA) three
times, and the phosphorylated proteins separated by resolution on
8% SDS-PAGE gels. Proteins were stained with CBB, dried, and
exposed to X-ray film [43,44]. To calculate substrate phosphor-
ylation activity, Histone IIAS (Sigma-Aldrich) was used as a
substrate. To evaluate the effects of PKA-specific inhibitor on
histone phosphorylation by TgPKA-C, GST-TgPKA-C and
Histone IIAS were incubated with 400, 200, 100, 50 and 25 mM
H89 (Promega) or 100 mM bovine PKI5–24 (synthetic peptide
derived from the active domain of PKI; Promega). TgPKA-C
activity was measured by scintillation counting of pieces of dried
gel corresponding to bands of histone in triplicate.
Phosphatase treatment
Following the kinase assays, labeled GST fusion proteins were
boiled to inactivate the kinase and incubated with l-protein
phosphatase (New England Biolabs) in accordance with the
manufacturer’s instructions.
Generation of GFP and TgPKA-R expressing parasites
Transfection of the expression plasmid to T. gondii RH/ht
2 was
performed as described previously [45]. Briefly, 30 mg of plasmid
DNA was electroporated into 5.0610
7 parasites using a Gene-
Pulser (Bio-Rad Laboratories, Tokyo, Japan) at 2000 V, 25 mF,
and 50 ohm. At 24 h after transfection, parasites were selected by
exposure to 50 mg/mL mycophenolic acid and xanthine for 48 h,
followed by a subsequent plaque purification. The recombinant
clones stably expressing GFP or TgPKA-R-3xFlag were designat-
ed RH/GFP or RH/TgPKA-R.
Parasite growth assay
RH/TgPKA-R or RH/GFP was inoculated onto confluent
Vero cell monolayers growing in four-chambered coverglass slides
(Nalge Nunc International, Rochester, NY) at a multiplicity of
infection (MOI) of 10 and allowed to invade host cells for 2 h at
37uC. Extracellular parasites were then removed by washing three
times with PBS(–) and returned to culture in complete medium
with or without the PKA-specific inhibitor. The final concentra-
tion of inhibitors H89 (Promega) and PKI14–22 (Calbiochem,
Temecula, CA) was 2 mM, and the volume of DMSO added was
the same as that of H89. After incubation for 12, 24, and 36 h, the
coverglass slides of RH/TgPKA-R were fixed with 4% parafor-
maldehyde in PBS(–) for 10 min, permeabilized by 0.1% Triton
X-100 in PBS(–) for 10 min, and blocked in 3% bovine serum
albumin and 5% skim milk in PBS(–). For the immunofluorescence
assay (IFA), the slides were incubated with mouse a-SAG1
(tachyzoite-specific surface antigen) polyclonal antibody (HyTest
Ltd., Turku, Finland) at a 1:1000 dilution for 1 h at room
temperature. After reaction with the primary antibody, slides were
washed three times with T-PBS [0.1% Tween 20 in PBS(–)], and
primary antibody was detected with Alexa 546-conjugated a-
mouse antibody (Invitrogen) at a 1:2000 dilution for 1 h at room
temperature, followed by five washes with T-PBS. The coverglass
slides of RH/GFP were fixed with 4% paraformaldehyde in
PBS(–) for 10 min and then washed three times with PBS(–). Each
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coverglass using Fluoromount-G (SouthernBiotech, Birmingham,
AL), and observed under a fluorescence microscope (Olympus,
Tokyo, Japan). Microscopic fields were chosen randomly to count
parasitophorous vacuoles up to three hundred. Vacuoles were
sorted by the numbers of tachyzoites inside, and average numbers
of tachyzoites per vacuole were calculated. Parasite growth was
determined by the number of parasites per vacuole. The
representative data of several experiments are shown in Figure 5.
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